JUPITER NEUROSCIENCES, INC. Proceeds from Notes Payable
JUPITER NEUROSCIENCES, INC. (JUNS) reported Proceeds from Notes Payable of $138.50 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-04-01
- JUPITER NEUROSCIENCES, INC. proceeds from notes payable for the quarter ending 2024-12-31 was $1.50K, a 98.85% decline year-over-year.
- JUPITER NEUROSCIENCES, INC. proceeds from notes payable for the quarter ending 2024-09-30 was $28.00K.
- JUPITER NEUROSCIENCES, INC. proceeds from notes payable for the quarter ending 2024-06-30 was $64.00K.
- JUPITER NEUROSCIENCES, INC. proceeds from notes payable for the quarter ending 2024-03-31 was $45.00K.
- JUPITER NEUROSCIENCES, INC. proceeds from notes payable for fiscal 2024 was $138.50K, a 64.49% decline from fiscal 2023.
- JUPITER NEUROSCIENCES, INC. proceeds from notes payable for fiscal 2023 was $390.00K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $29.50K derived: sum of 2 quarters · filed 2026-04-01 | $93.50K derived: sum of 3 quarters · filed 2026-04-01 | $138.50K 10-K · filed 2026-04-01 |
| 2024-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $92.00K derived: sum of 2 quarters · filed 2025-11-14 | $137.00K 10-Q · filed 2025-11-14 | $267.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $109.00K 10-Q · filed 2025-08-19 | $239.00K derived: sum of 3 quarters · filed 2025-08-19 | |
| 2024-03-31 | $45.00K 10-Q · filed 2025-05-15 | $175.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $390.00K 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $260.00K 10-Q · filed 2024-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |